The surgery of prostate cancer: An update of contemporary radical prostatectomy and brachytherapy series

Seminars in Surgical Oncology

Volumn 17, Issue 3, 1999, Pages 213-218

  Krumholtz, Jason S ^a   Andriole, Gerald L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic hormonal agents; Brachytherapy; Disease free survival; Impotence; Patient selection; Postoperative complications; Prostatectomy; Prostatic neoplasms; Radioisotopes; Radiotherapy; Survival rate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; DOSIMETRY; HUMAN; INTERMETHOD COMPARISON; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT FAILURE;

BRACHYTHERAPY; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0032880448     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199910/11)17:3<213::AID-SSU11>3.0.CO;2-P     Document Type: Review

References (51)

1. Montie JE, Wood DP Jr, Pontes JE, et al: Adenocarcinoma of the prostate in cysloprostatectomy specimens removed for bladder cancer. Cancer 1989;63:381-385.
2. Rich AR: On the frequency of occult carcinoma of the prostate. J Urol 1935;33:215-223.
3. Franks LM: Latent carcinoma of the prostate. J Pathol Bacteriol 1954;68:603-616.
4. McNeal JE: Origin and development of carcinoma in the prostate. Cancer 1969; 23:24-34.
5. Coffey DS: Prostate cancer. An overview of an increasing dilemma [Review]. Cancer 1993; 71(3 Suppl):880-886.
6. Stamey TA, Freiha FS, McNeal JE, et al: Localized prostate. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-938.
7. Sakr WA, Haas GP, Cassin BF, et al: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150(2 Pt 1):379-385.
8. Ohori M, Wheeler TM, Dunn JK, et al: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152(5 Pt 2):1714-1720.
9. Epstein JI, Walsh PC, Brendler CB: Radical prostatectomy for impalpable prostate cancer. The Johns Hopkins experience with tumors found on transurethral resection (stages T1a and T1b and on needle biopsy (stage T1c) [Review]. J Urol 1994;152(5 Pt 2): 1721-1729.
10. Johansson JE, Adami HO, Andersson SO, et al: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-2196.
11. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993;269: 2650-2658.
12. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-248.
13. Aus G, Hugosson J, Norlen L: Long-term survival and mortality in prostate cancer treated with non-curative intent [Review]. J Urol 1995;154(2 Pt 1):460-465.
14. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 Pt 2):1831-1836.
15. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate term results. J Urol 1998;160(6 Pt 2):2428-2434.
16. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomical radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
17. Trapasso JG, deKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-1825.
18. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 Pt 2):1850-1857.
19. Catalona WJ, Smith DS: Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 Pt 2):1837-1842.
20. Epstein JI, Pizov G, Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-3593.
21. Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152(5 Pt 2):1843-1849.
22. Partin AW, Walsh PC: Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer [letter;comment]. J Urol 1994; 152:172-173.
23. Walsh PC, Donker PJ: Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492-497.
24. Catalona WJ, Basler JW: Return of erections and urinary continence following nerve-sparing radical retropubic prostatectomy. J Urol 1993;150:905-907.
25. Leandri P, Rossignol G, Gautier JR, Ramon J: Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992;147(3 Pt 2):883-887.
26. Quinlan DM, Epstein JI, Carter BS, Walsh PC: Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol 1991;145:998-1002.
27. Ramon J, Rossignol G, Leandri P, Gautier JR: Morbidity of radical retropubic prostatectomy following previous prostate resection. J Surg Oncol 1994;55:14-19.
28. Drago JR, Badalament RA, Nesbitt JA: Radical prostatectomy 1972-1987 single institutional experience: comparison of standard radical prostatectomy and nerve-sparing technique. Urology 1990;35:377-380.
29. Catalona WJ: Surgical management of prostate cancer. Cancer 1995;75(7 Suppl):1903-1908.
30. Reiner WG, Walsh PC: An anatomic approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic prostatectomy. J Urol 1979;121:198-200.
31. Andriole GL, Smith DS, Rao G, et al: Early complications of contemporary anatomical radical retropubic prostatectomy. J Urol 1994;152(5 Pt 2):1858-1860.
32. Koprowski CD, Berkenstock KG, Borofski AM, et al: External beam irradiation versus 125 iodine implant in the definitive treatment of prostate carcinoma. Int J Radiat Oncol Biol Phys 1991;21:955-960.
33. Kuban DA, el-Mahdi AM, Schellhammer PF: I-125 interstitial implantation for prostate cancer. What have we learned 10 years later? Cancer 1989;63:2415-2420.
34. Morton JD, Peschel RE: Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer. Int J Radiat Oncol Biol Phys 1988;14:1153-1157.
35. Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the liner quadratic model. Int J Radiat Oncol Biol Phys 1992;23:81-87.
36. Grimm PD, Blasko JC, Ragde H: Ultrasound-guided transperineal implantation of iodine 125 and palladium 103 for the treatment of early stage prostate cancer. Atlas Urol Clin North Am 1994; 2:113-125.
37. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
38. Critz FA, Levinson AK, Williams WH, et al: The PSA nadir goal for radiotherapy of prostate cancer is (less than or equal to) 0.2 ng/mL [Abstract]. J Urol 1998;159(5 Suppl):218 (#844).
39. Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [Review]. Cancer 1998;83:989-1001.
40. Kaye KW, Olson DJ, Payne JT: Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach [Review]. J Urol 1995;153(3 Pt 2):1020-1025.
41. Stock RG, Stone NN, DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996;77:2386-2392.
42. Wallner K, Roy J, Harrison L: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostate carcinoma. J Clin Oncol 1996;14:449-453.
43. Stokes SH, Real JD, Adams PW, et al: Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;37:337-341.
44. Beyer DC, Priestley JB Jr: Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol Biol Phys 1997;37:559-563.
45. Levinson AK, Critz FA, Williams H: Prostate cancer treated by simultaneous radiotherapy: I-125 prostate implant followed by external-beam radiation [Abstract]. J Urol 1998;159(5 Suppl):63 (#236).
46. Blasko JC, Grimm PD, Ragde H: External beam irradiation with palladium-103 implantation for prostate carcinoma [Abstract]. Int J Radiat Oncol Biol Phys 1994;30:219.
47. Dattoli MJ, Wasserman SG, Koval JM, et al: Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer [Abstract]. Int J Radiat Oncol Biol Phys 1995;32:251.
48. Borghede G, Hedelin H, Holmang S, et al: Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostate carcinoma. Radiother Oncol 1997;44:237-244.
49. Blasko JC, Grimm PD, Ragde H: Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol 1993;3:240-249.
50. Polascik TJ, Pound CR, DeWeese TL, Walsh PC: Comparison of radical prostatectomy and iodine 15 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis [Review]. Urology 1998;51:884-890.
51. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.